Last reviewed · How we verify
PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
This study is comparing two combinations of chemotherapy treatments in patients with metastatic pancreatic cancer. Half the participants will receive FOLFOX-A and the other half will receive AG. Treatment will continue until progression or patient/clinican decision or intolerable toxicity.
Details
| Lead sponsor | Judith Dixon-Hughes |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 500 |
| Start date | Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Jan 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Neoplasms Pancreatic
Interventions
- FOLFOX-A
- Gemcitabe and Abraxane
- G-CSF
Countries
United Kingdom